Ocular Drug Delivery – State-of-the-Art and New Concepts | CN 6639
Venue
WYNDHAM GARDEN Berlin MitteOsloer Str. 1
13359 Berlin
Phone:+49 30 495 000-0
Fax:+49 30 495 000-495
E-mail:info@wyndamgardenberlin.com
Workshop programme for download
Target groups
Scientists, technical experts, project and line managers from various areas of ocular drug product development involved into research and development of ophthalmic drug products for new drug candidates (small and large molecules).
Objective
Outline
There is an increasing interest in developing novel and improved medicines for the treatment of ocular diseases such as age related macular degeneration (AMD), diabetic retinopathies, glaucoma, dry eye.
World leading experts from Europe and America working in preclinical and clinical R&D areas in academia, industry and CROs will provide insights to formulation related development aspects and discuss adequate approaches such as: - Basic aspects of ocular diseases and treatment options by using modern drug delivery systems ranging from eye drops to controlled release systems- Drug transport and pharmacokinetics in the eye - Overview on available and novel formulations principles and drug delivery systems - Challenges and hurdles in the development of novel drug delivery concepts including packaging - Options for preclinical and clinical testing ocular delivery systems (CRO’s) - Case studies
Speaker
Professor emeritus Dr. Robert Gurny
Professor emeritus Dr. Robert Gurny, University of Geneva, former President of the School of Pharmaceutical Sciences at the University of Geneva, Switzerland is a world leading expert in the area of ophthalmic formulations and drug delivery. His is active in the field of ocular drug delivery since more than thirty years and has co-authored over 150 papers in the field.
Dr. Rainer Alex
Dr. Rainer Alex, has more than 25 years of experience in the area of drug product development and drug delivery research. He is currently involved into early evaluation and development activities for ophthalmic drug products in the Preclinical and Early Development unit at the Roche Innovation Center Basel at F. Hoffmann – La Roche AG in Basel.
Registration fee
| Regular Fee | Reduced Fee |
|---|---|
| 1,590.00 € | 1,460.00 € |
Organizer(s)
APV-Office
Dr. Martin Bornhöft
Phone: +49 6131 9769-0
Fax: +49 6131 9769-69
E-mail: apv@apv-mainz.de
www: https://www.apv-mainz.de/